Cardiomyopathy Therapies

Cardiomyopathy Therapies


Global Cardiomyopathy Therapies Market to Reach US$3.4 Billion by 2030

The global market for Cardiomyopathy Therapies estimated at US$3.0 Billion in the year 2023, is expected to reach US$3.4 Billion by 2030, growing at a CAGR of 1.7% over the analysis period 2023-2030. Dilated Cardiomyopathy, one of the segments analyzed in the report, is expected to record a 1.9% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Hypertrophic Cardiomyopathy segment is estimated at 1.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$822.0 Million While China is Forecast to Grow at 3.0% CAGR

The Cardiomyopathy Therapies market in the U.S. is estimated at US$822.0 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$625.0 Million by the year 2030 trailing a CAGR of 3.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 1.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.1% CAGR.

Global Cardiomyopathy Therapies Market - Key Trends and Drivers Summarized

Cardiomyopathy is a complex and heterogeneous group of heart muscle diseases that impair the heart`s ability to pump blood effectively. These conditions can be classified into several types, including dilated, hypertrophic, restrictive, and arrhythmogenic right ventricular cardiomyopathy. Each type has distinct etiologies, pathophysiologies, and clinical presentations, necessitating tailored therapeutic approaches. Current treatment options for cardiomyopathy range from pharmacological interventions such as beta-blockers, ACE inhibitors, and anticoagulants, to non-pharmacological strategies, including lifestyle modifications and the use of implantable devices like pacemakers and defibrillators. In severe cases, patients may require advanced therapies such as cardiac resynchronization therapy, ventricular assist devices, or even heart transplantation. Despite the variety of treatments available, managing cardiomyopathy remains challenging due to its progressive nature and the potential for sudden cardiac death.

Recent advancements in the understanding of molecular and genetic underpinnings of cardiomyopathy have paved the way for innovative therapeutic approaches. Gene therapy and molecular-targeted therapies are at the forefront of research, offering potential curative solutions for certain genetic forms of cardiomyopathy. For instance, CRISPR-Cas9 gene editing and RNA interference are being explored to correct or silence defective genes responsible for cardiomyopathy. Additionally, the development of novel pharmacological agents, such as myosin inhibitors and selective cardiac myosin activators, is aimed at directly modulating cardiac contractility and improving heart function. Stem cell therapy also holds promise, with ongoing clinical trials investigating its potential to regenerate damaged heart tissue and restore myocardial function. These cutting-edge therapies are complemented by advancements in diagnostic tools, including next-generation sequencing and advanced imaging techniques, which facilitate early and precise diagnosis, thereby enabling timely and targeted interventions.

The growth in the cardiomyopathy therapies market is driven by several factors. The rising prevalence of cardiovascular diseases, particularly in aging populations, has significantly increased the demand for effective cardiomyopathy treatments. Technological advancements in diagnostic and therapeutic modalities have expanded the range of available treatment options, making it possible to offer more personalized and effective care. Increased awareness and understanding of cardiomyopathy among patients and healthcare providers have led to earlier diagnosis and intervention, improving patient outcomes. Furthermore, substantial investments in research and development by pharmaceutical companies and academic institutions are accelerating the discovery and commercialization of novel therapies. Supportive government policies and favorable reimbursement frameworks in many regions are also playing a crucial role in making advanced treatments accessible to a broader patient population. Additionally, the integration of digital health technologies, such as remote monitoring and telemedicine, is enhancing patient management and adherence to therapy, thereby driving market growth. Collectively, these factors are fostering a dynamic and rapidly evolving market for cardiomyopathy therapies.

Select Competitors (Total 86 Featured) -
  • Abbott Cardiovascular
  • Alexion Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bio-Rad Laboratories, Inc.
  • Bristol Myers Squibb company
  • Cardiol Therapeutics, Inc.
  • Cipla Ltd
  • Cytokinetics, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Diagnostics (Schweiz) AG
  • Tenaya Therapeutics;
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Global Economic Update
Cardiomyopathy Therapies - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Prevalence of Cardiovascular Diseases Spurs Demand for Cardiomyopathy Therapies
Technological Advancements in Diagnostic Modalities Propel Growth
Gene Therapy and Molecular-Targeted Treatments Expand Addressable Market Opportunity
Increased Awareness and Early Diagnosis Strengthen Business Case for Innovative Therapies
Development of Novel Pharmacological Agents Generates New Market Opportunities
Here`s How Advancements in Stem Cell Therapy Drive Market Dynamics
Growing Focus on Personalized Medicine Drives Adoption of Tailored Treatment Approaches
Integration of Digital Health Technologies Sustains Growth in Patient Management
Expansion of Telemedicine Services Enhances Access to Cardiomyopathy Care
Rising Geriatric Population Throws the Spotlight On Need for Comprehensive Cardiac Care
Here`s the Story: Impact of Advanced Imaging Techniques on Early and Accurate Diagnosis
Evolution of Multimodal Treatment Strategies Drives Comprehensive Patient Care
Advances in Biomarker Discovery Generate Opportunities for Precision Medicine
Trend towards Outpatient Cardiac Care Spurs Demand for Non-Invasive Therapies
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Cardiomyopathy Therapies Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Cardiomyopathy Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Cardiomyopathy Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Dilated Cardiomyopathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Dilated Cardiomyopathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Dilated Cardiomyopathy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Hypertrophic Cardiomyopathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Hypertrophic Cardiomyopathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Hypertrophic Cardiomyopathy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 14: USA Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 15: USA Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: USA 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
CANADA
TABLE 17: Canada Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 18: Canada Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: Canada 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
JAPAN
Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 20: Japan Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 21: Japan Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: Japan 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
CHINA
Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 23: China Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 24: China Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: China 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
EUROPE
Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 26: Europe Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 27: Europe Historic Review for Cardiomyopathy Therapies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: Europe 16-Year Perspective for Cardiomyopathy Therapies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 29: Europe Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: Europe Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: Europe 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
FRANCE
Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 32: France Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: France Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: France 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
GERMANY
Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 35: Germany Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: Germany Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: Germany 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
ITALY
TABLE 38: Italy Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: Italy Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: Italy 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
UNITED KINGDOM
Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 41: UK Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: UK Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: UK 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
SPAIN
TABLE 44: Spain Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: Spain Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: Spain 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
RUSSIA
TABLE 47: Russia Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: Russia Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: Russia 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: Rest of Europe Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: Rest of Europe 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 54: Asia-Pacific Historic Review for Cardiomyopathy Therapies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Asia-Pacific 16-Year Perspective for Cardiomyopathy Therapies by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Asia-Pacific Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Asia-Pacific 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
AUSTRALIA
Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 59: Australia Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: Australia Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Australia 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
INDIA
Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 62: India Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: India Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: India 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 65: South Korea Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: South Korea Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: South Korea 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: Rest of Asia-Pacific Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
LATIN AMERICA
Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 71: Latin America Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 72: Latin America Historic Review for Cardiomyopathy Therapies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: Latin America 16-Year Perspective for Cardiomyopathy Therapies by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 74: Latin America Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: Latin America Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Latin America 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 77: Argentina Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: Argentina Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: Argentina 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
BRAZIL
TABLE 80: Brazil Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: Brazil Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: Brazil 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
MEXICO
TABLE 83: Mexico Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: Mexico Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Mexico 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Rest of Latin America Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Rest of Latin America 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
MIDDLE EAST
Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 89: Middle East Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 90: Middle East Historic Review for Cardiomyopathy Therapies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Middle East 16-Year Perspective for Cardiomyopathy Therapies by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 92: Middle East Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: Middle East Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Middle East 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
IRAN
TABLE 95: Iran Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Iran Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Iran 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
ISRAEL
TABLE 98: Israel Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Israel Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Israel 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Saudi Arabia Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Saudi Arabia 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 104: UAE Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 105: UAE Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: UAE 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: Rest of Middle East Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Rest of Middle East 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
AFRICA
Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 110: Africa Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: Africa Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: Africa 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings